UCLB spinout Autolus Therapeutics has been named in The Guardian’s ‘Six Firms to Watch in 2023’.
Spun out from University College London in 2014, the business develops programmed T cell therapies: also known as living medicines, they re-engineer patients’ immune systems to recognise and attack cancer.
Four years ago, Autolus floated on Nasdaq, raising $160m, and has just raised a further $150m (£125m) from investors, including the British life science investment firm Syncona. It also counts Blackstone Life Sciences among its backers, which has invested up to $250m in one of the largest ever private financings of a UK biotech company.
Read the full story from The Guardian.